- Home
- MYGN vs DAWN Comparison
MYGN vs DAWN Comparison
Compare MYGN & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- DAWN
- Stock Information
- Founded
- MYGN 1991
- DAWN 2018
- Country
- MYGN United States
- DAWN United States
- Employees
- MYGN N/A
- DAWN N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- DAWN Health Care
- Exchange
- MYGN Nasdaq
- DAWN Nasdaq
- Market Cap
- MYGN 642.0M
- DAWN 624.8M
- IPO Year
- MYGN 1995
- DAWN 2021
- Fundamental
- Price
- MYGN $7.40
- DAWN $6.99
- Analyst Decision
- MYGN Hold
- DAWN Strong Buy
- Analyst Count
- MYGN 13
- DAWN 7
- Target Price
- MYGN $13.50
- DAWN $27.86
- AVG Volume (30 Days)
- MYGN 1.3M
- DAWN 922.7K
- Earning Date
- MYGN 11-06-2025
- DAWN 10-29-2025
- Dividend Yield
- MYGN N/A
- DAWN N/A
- EPS Growth
- MYGN N/A
- DAWN N/A
- EPS
- MYGN N/A
- DAWN N/A
- Revenue
- MYGN $832,900,000.00
- DAWN $187,638,000.00
- Revenue This Year
- MYGN $0.17
- DAWN $12.56
- Revenue Next Year
- MYGN $6.19
- DAWN $48.02
- P/E Ratio
- MYGN N/A
- DAWN N/A
- Revenue Growth
- MYGN 3.83
- DAWN 2190.50
- 52 Week Low
- MYGN $3.76
- DAWN $5.64
- 52 Week High
- MYGN $29.30
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- MYGN 66.01
- DAWN 46.39
- Support Level
- MYGN $7.13
- DAWN $6.90
- Resistance Level
- MYGN $7.80
- DAWN $7.58
- Average True Range (ATR)
- MYGN 0.44
- DAWN 0.26
- MACD
- MYGN 0.04
- DAWN -0.07
- Stochastic Oscillator
- MYGN 78.61
- DAWN 10.78
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.